Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:adjuvant |
aluminum hydroxide
|
| gptkbp:antigen |
protective antigen
|
| gptkbp:approves |
gptkb:1970
gptkb:FDA |
| gptkbp:availability |
limited
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:booster_required |
yes
|
| gptkbp:brand |
gptkb:Bio_Thrax
|
| gptkbp:clinical_trial |
Phase I, II, III
|
| gptkbp:clinical_use |
pre-exposure and post-exposure
|
| gptkbp:contraindication |
severe allergic reaction
|
| gptkbp:developed_by |
gptkb:United_States_Army
|
| gptkbp:dosage_form |
3 doses
|
| gptkbp:duration_of_immunity |
at least 1 year
|
| https://www.w3.org/2000/01/rdf-schema#label |
anthrax vaccine
|
| gptkbp:is_effective_against |
high against inhalational anthrax
|
| gptkbp:is_recommended_for |
gptkb:military_personnel
|
| gptkbp:is_vulnerable_to |
gptkb:educational_campaigns
government and private sectors varies by provider ongoing research public perception issues subunit vaccine monitored by health authorities studies on long-term immunity ongoing safety assessments adverse event reporting system over 90% in clinical studies 0, 7, 21 or 28 days 3 doses followed by annual booster collaborations with international health organizations CDC guidelines contributes to global health security developed after 9/11 attacks managed by CDC new delivery methods being explored reduced incidence of anthrax cases |
| gptkbp:manufacturer |
gptkb:Emergent_Bio_Solutions
|
| gptkbp:post_exposure_prophylaxis |
effective when combined with antibiotics
|
| gptkbp:public_health_importance |
biological threat mitigation
|
| gptkbp:regulatory_compliance |
licensed in the U. S.
|
| gptkbp:research_focus |
improved formulations
|
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
headache
nausea fever mild pain at injection site |
| gptkbp:suitable_for |
pregnant women
|
| gptkbp:target_audience |
high-risk individuals
|
| gptkbp:targets |
gptkb:disease
|
| gptkbp:type |
inactivated vaccine
|
| gptkbp:used_in |
bioterrorism preparedness
|
| gptkbp:vaccine_crisis_management |
part of emergency response plans
|
| gptkbp:vaccine_ethics |
debates on mandatory vaccination
|
| gptkbp:vaccine_public_health_policy |
integrated into national health strategies
|
| gptkbp:vaccine_regulations |
subject to federal oversight
|
| gptkbp:vaccine_research_collaborations |
academic and industry partnerships
|
| gptkbp:bfsParent |
gptkb:Institut_Pasteur
|
| gptkbp:bfsLayer |
4
|